metastatic non-small cell lung cancer

Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class
Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class
Fierce Biotech
Merck
Keytruda
clinical trials
vibostolimab
non-small cell lung cancer
metastatic non-small cell lung cancer
Flag link:
Exelixis drug fails PhIII lung cancer trial with Cabometyx and Tecentriq combo
Exelixis drug fails PhIII lung cancer trial with Cabometyx and Tecentriq combo
Endpoints
Exelixis
Cabometyx
Tecentriq
metastatic non-small cell lung cancer
clinical trials
Flag link:
Propel fails to propel Nektar
Propel fails to propel Nektar
EP Vantage
Nektar Therapeutics
Merck
bempegaldesleukin
clinical trials
metastatic non-small cell lung cancer
Flag link:
WCLC: AstraZeneca's detailed Imfinzi, tremelimumab data in metastatic NSCLC are far from a clear-cut win
WCLC: AstraZeneca's detailed Imfinzi, tremelimumab data in metastatic NSCLC are far from a clear-cut win
Fierce Pharma
WCLC
AstraZeneca
tremelimumab
metastatic non-small cell lung cancer
Flag link:
Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy
Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy
Yahoo/Zacks.com
Iovance
LN-145
metastatic non-small cell lung cancer
Flag link:
Novartis’ Autoimmune Drug Not Up for the Challenge in Phase III Cancer Trial
Novartis’ Autoimmune Drug Not Up for the Challenge in Phase III Cancer Trial
BioSpace
Novartis
canakinumab
clinical trials
metastatic non-small cell lung cancer
Flag link:
Setback for Novartis drug in advanced lung cancer trial
Setback for Novartis drug in advanced lung cancer trial
Biopharma Reporter
Novartis
clinical trials
canakinumab
metastatic non-small cell lung cancer
Flag link:
FDA Approves Merck KGaA's Tepmetko for Aggressive Lung Cancer
FDA Approves Merck KGaA's Tepmetko for Aggressive Lung Cancer
BioSpace
Merck KGaA
Tepmetko
FDA
metastatic non-small cell lung cancer
Flag link:
In a first, Janssen submits lung cancer bispecific hopeful amivantamab to the FDA
In a first, Janssen submits lung cancer bispecific hopeful amivantamab to the FDA
Fierce Biotech
Janssen
non-small cell lung cancer
FDA
amivantamab
JNJ
metastatic non-small cell lung cancer
Flag link:
BeiGene beefs up PD-1 data with positive PhIII results for tislelizumab, this time in metastatic NSCLC
BeiGene beefs up PD-1 data with positive PhIII results for tislelizumab, this time in metastatic NSCLC
Endpoints
BeiGene
metastatic non-small cell lung cancer
Flag link:
FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC
FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC
Pharmaceutical Business Review
Bristol-Myers Squibb
Opdvio
Yervoy
metastatic non-small cell lung cancer
Flag link:
FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC
FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC
Pharmaceutical Business Review
Genentech
Roche
Tecentriq
FDA
metastatic non-small cell lung cancer
Flag link:
Roche’s TIGIT drug shows promise in untreated lung cancer
Roche’s TIGIT drug shows promise in untreated lung cancer
Pharmaforum
Roche
ASCO 2020
tiragolumab
Tecentriq
metastatic non-small cell lung cancer
Flag link:
Takeda gets FDA breakthrough therapy status for mobocertinib to treat certain type of lung cancer
Takeda gets FDA breakthrough therapy status for mobocertinib to treat certain type of lung cancer
Pharmaceutical Business Review
Takeda
FDA
mobocertinib
metastatic non-small cell lung cancer
Flag link:
J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation
J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation
BioSpace
Janssen
JNJ
FDA
JNJ-6372
breakthrough therapy
metastatic non-small cell lung cancer
Flag link:
Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC
Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC
Pharmaceutical Business Review
Janssen
JNJ
FDA
JNJ-6372
metastatic non-small cell lung cancer
Flag link:
Sandoz launches oncology generic gefitinib in 13 EU countries
Sandoz launches oncology generic gefitinib in 13 EU countries
Pharmaceutical Business Review
Sandoz
Novartis
generics
gefitinib
metastatic non-small cell lung cancer
Flag link:
Lilly's combo treatment meets main goal in lung cancer late-stage study
Lilly's combo treatment meets main goal in lung cancer late-stage study
Yahoo/Reuters
Eli Lilly
Cyramza
clinical trials
metastatic non-small cell lung cancer
Roche
erlotinib
Flag link:
Merck's Keytruda faces delay in first-line approval decision
Merck's Keytruda faces delay in first-line approval decision
Biopharma Dive
FDA
Keytruda
Merck
metastatic non-small cell lung cancer
Flag link:
FDA Grants Pfizer's Xalkori Breakthrough Therapy Status for Two New Indications
FDA Grants Pfizer's Xalkori Breakthrough Therapy Status for Two New Indications
CP Wire
Pfizer
Xalkori
metastatic non-small cell lung cancer
FDA
breakthrough therapies
anaplastic large-cell lymphoma
Flag link:

Pages